GCT-103 (SQ-SHED)
Pediatric Cerebral Palsy
Phase 1Active (Autologous trial ongoing; allogeneic planned)
Key Facts
Indication
Pediatric Cerebral Palsy
Phase
Phase 1
Status
Active (Autologous trial ongoing; allogeneic planned)
Company
About Kidswell Bio
Japanese biotech developing SHED-based cell therapies for pediatric neurological disorders and operating a dual business model with biosimilars.
View full company profile